Evidence map›Paper›PMID 31993931›Full record

ArticleJournal of molecular neuroscience : MN2020

Ethical Dilemmas Linked to Fragile X Testing of Minors-a Preliminary Survey Among Professionals.

Lidia V Gabis, Shahar Shefer, Annick Raas-Rothschild

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular neuroscience : MN, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Lidia V GabisWeinberg Child Development Center at Safra Children's Hospital, Tel Hashomer, Israel. lidia.Gabis@sheba.health.gov.il.
Shahar SheferWeinberg Child Development Center at Safra Children's Hospital, Tel Hashomer, Israel.ORCID http://orcid.org/0000-0003-4482-7491
Annick Raas-RothschildSackler School of Medicine at Tel Aviv University, Tel Aviv, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Asymptomatic female carriers of the FMR1 premutation at childbearing age have been mostly identified through prenatal genetic testing, which is routinely proposed in Israel. During the last few years, a premutation phenotype in males and females has been defined-FXAND, including neuropsychiatric disorder, learning difficulties, endocrine dysfunction, and premature ovarian failure. So when a family at risk is identified, should individuals be tested for premutation even if minors? In order to understand what professionals' views are with regard to testing FMR1 premutation in minors, we performed a questionnaire testing both ethical attitudes and knowledge. Eighty-two percent of professionals would positively consider fragile X testing in minors, and an additional 15.4% would consider it in boys only. The specific phenotype of full mutation is recognized well by health professionals, while the premutation phenotype is not well known. There is a need to expand awareness on the fragile X premutation phenotype through better information. Testing of fragile X premutation status in minors should be considered, when at risk due to family history.

Indexed as

Health Knowledge, Attitudes, PracticeMinorsAdultFemaleFragile X Messenger Ribonucleoprotein 1Fragile X SyndromeGenetic Carrier ScreeningHealth PersonnelHumansMalePhenotypeSex FactorsSurveys and QuestionnairesFMR1 protein, humanFragile X Messenger Ribonucleoprotein 1FMR1 premutationFragile XPreventionSiblings

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.